Trial Testing MS1819 Plus PERT for Exocrine Pancreatic Insufficiency Now Dosing in Turkey

Trial Testing MS1819 Plus PERT for Exocrine Pancreatic Insufficiency Now Dosing in Turkey
0
(0)

A clinical trial testing AzurRx BioPharma‘s investigational therapy MS1819, in combination with the current standard care for the treatment of severe exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF), has dosed its first two participants, AzurRx announced.

“In the midst of a global pandemic and unpredictable obstacles, we are very encouraged to see our Combination therapy trial moving forward at one of the clinical testing sites in Turkey,” James Sapirstein, president and CEO of AzurRx, said in a press release.

In people with CF, thick mucus forms in multiple organs, including the pancreas. This mucus blocks the release of enzymes needed to properly digest food, particularly fats, resulting in EPI.

The current standard-of-care for EPI is the use of porcine-derived pancreatic enzyme replacement therapy (PERT), where pancreatic enzymes derived from pigs are used to functionally replace the missing pancreatic enzymes in the digestive tract. However, even with PERT, many people with EPI will have worse-than-typical fat digestion, which can result in unpleasant symptoms and impair proper nutrition.

More specifically, mean CFA at the MS1819 700 mg/day plus standard care group was 88.4%, 87.2% in the 1,200 mg/day dose group, and 86.5% in the 2,240 mg/day group, compared to baseline level (78.4%).

Improvements also were seen in secondary parameters, such as body weight, stool properties (consistency, weight, and frequency of evacuations), and the incidence of steatorrhea (excessive amount of fat in feces).

No adverse safety events were reported.

The study is still enrolling participants in Hungary and Turkey; more information is available here. According to the company, there are five active sites recruiting in Turkey.

“We expect to release topline results [from the trial] in the second quarter of next year,” Sapirstein said. “We are optimistic the results will build on the encouraging data we received earlier this year and hope we will be one step closer to improving the lives of thousands of patients suffering from cystic fibrosis.”

MS1819 also is being evaluated in another clinical trial, OPTION 2 (NCT04375878), which is comparing MS1819 to traditional pig-derived PERT in people with EPI. The trial is recruiting in the U.S. and Poland; more information is available here.

Marisa, a science writer, holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Total Posts: 336

Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

×
Marisa, a science writer, holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Latest Posts
  • Kaftrio use in EU
  • Bronchitol for CF
  • Kalydeco
  • MS1819

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?